Related Experiment Video

Updated: Oct 16, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

703

NOX1/4 Inhibitor GKT-137831 Improves Erectile Function in Diabetic Rats by ROS Reduction and Endothelial Nitric Oxide

Bingyan Zhou1, Yinwei Chen2, Huixing Yuan2

  • 1Department of Urology and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The Journal of Sexual Medicine
|October 15, 2021
PubMed
Abstract

Insights

GKT-137831, an NOX1/4 inhibitor, significantly improved erectile function in diabetic rats by reducing oxidative stress and inflammation. This compound shows promise for treating type 1 diabetic erectile dysfunction.

Area of Science:

  • Urology
  • Endocrinology
  • Pharmacology

Background:

  • Oxidative stress contributes to hyperglycemia-induced erectile dysfunction.
  • GKT-137831, a NOX1/4 inhibitor, reduces reactive oxygen species (ROS) but its effect on erectile function was unclear.

Purpose of the Study:

  • Investigate the efficacy of NOX1/4 inhibition using GKT-137831 in improving diabetic erectile dysfunction (ED) in a rat model.

Main Methods:

  • Type 1 diabetes mellitus (DM) was induced in Sprague Dawley rats using streptozotocin.
  • Diabetic erectile dysfunction (DMED) was confirmed, and rats were divided into control, vehicle, and GKT-137831 treatment groups.
  • Erectile function was assessed via cavernous nerve electrostimulation; molecular markers of oxidative stress, inflammation, autophagy, and apoptosis were analyzed.

Main Results:

  • GKT-137831 treatment improved erectile function by 70% in DMED rats compared to controls.
  • The treatment ameliorated endothelial dysfunction, reduced oxidative stress, inflammatory responses, and excessive autophagy in the corpus cavernosum.
  • Key signaling pathways including nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) were modulated.

Conclusions:

  • NOX1/4 inhibition with GKT-137831 effectively improves erectile function in a type 1 diabetic rat model.
  • GKT-137831 demonstrates potential as a therapeutic agent for type 1 DMED by targeting oxidative stress, inflammation, and autophagy.
Keywords:
AutophagyErectile dysfunctionGKT-137831InflammatoryReactive oxygen species

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.5K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
292
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
477
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
909
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
572